Pfizer sued by Texas over vaccine efficacy - Breaking The News
Download our appPlay StoreApp Store

Pfizer sued by Texas over vaccine efficacy

EPA-EFE/CAROLINE BREHMAN

Texas Attorney General Ken Paxton announced on Thursday that his office sued Pfizer Inc.

At the center of the lawsuit is Pfizer's claim that its coronavirus vaccine was "95% effective." The state of Texas accused the company of deceiving the public by making a "highly misleading" claim about its product, which, "buoyed by the company's misrepresentations, enriched the company enormously," according to the text of the document.

The pharmaceutical firm "created the false impression that its vaccine provided a substantially greater amount of protection against COVID-19 infection than what it afforded in reality" and tried to "censor persons who sought to disseminate truthful information that would undermine... its ongoing deception," it was alleged in the lawsuit.

Related Stocks
Pfizer
Related News
Pfizer CEO says tariff uncertainty limits investment
Pfizer Inc. CEO Albert Bourla (pictured) said on Tuesday that uncertainty surrounding US President Donald Trump's proposed pharmaceutical tariffs is discouraging the company from expanding in the US. "If I know that there will not be tariffs ... then there are tremendous investments that can happen in this country," he stated, highlighting opportunities in both R&D and manufacturing."In periods of uncertainty, everybody is controlling their cost ... and is...
Pfizer's Q1 revenue down by 8% to $13.7 billion
Pfizer Inc. announced on Tuesday that its revenue in the first quarter of the fiscal year 2025 saw an annual rise of 8% to reach $13.7 billion. The pharmaceutical company's net income declined by 5% year-on-year to land at $2.97 billion. Meanwhile, its diluted earnings per share (EPS) went down by 5% to $0.52."Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the...
Pfizer ends weight loss pill trial after liver injury in one patient
Pfizer Inc. announced on Monday that it is halting the development of its daily pill for chronic weight management, danuglipron, after one of the participants in the trial experienced drug-induced liver injury.The company stated that a participant in one of the dose-optimization studies experienced a liver enzyme elevation but did not have any liver-related symptoms or side effects. The enzymes returned to their normal levels once the patient stopped taking the...
US attorney allegedly probes tip about Pfizer's vaccine timing
The United States Attorney's office is investigating a claim by the British pharmaceutical company GSK about the "delayed" announcement of the success of Pfizer's Covid vaccine in 2020, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.According to the report, Pfizer's former employee, Phil Dormitzer, who later became a senior scientist at Pfizer's rival company, GSK, told his colleagues at GSK that Pfizer delayed the...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.